TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 6.500

-6.3%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kathleen who wrote (14)	9/4/1997 2:27:00 PM
From: Leman	of 557

Thursday September 4 1:37 PM EDT Company Press Release Source: Genesis Merchant Group Securities Genesis Raises Rating on Targeted Genetics to Strong Buy SAN FRANCISCO, Sept. 4 /PRNewswire/ -- Genesis Merchant Group Securities today raised its rating on Targeted Genetics Corporation (Nasdaq:TGEN) from Buy to Strong Buy and is reiterating its 12-month price target of $15 per share. Genesis associate analyst D. Curtis Hogue cites three main drivers moving the stock price in the next few months: a potential for a corporate partner to invest in its cystic fibrosis program; new results to be announced from the company's second Phase I study; and additional results expected from its clinical studies for both cystic fibrosis and cancer gene therapies. ``Data from Targeted Genetics' Phase I trials of its AAV-CFTR product, released in October 1996, demonstrated safety and biological activity and appear to be significantly better than previous CF gene therapy studies. This data indicates the probability of success with the AAV-CFTR product is very high,'' states Hogue. He thinks that at the current price, the stock represents a significant buying opportunity. ``Based on the revenues I foresee,'' says Hogue, ``the potential for the AAV-CFTR product alone justifies a share price of $7 to $8. TGEN's clinical pipeline and patent portfolio add considerable value beyond this level.'' SOURCE: Genesis Merchant Group Securiti

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next